83 related articles for article (PubMed ID: 29088773)
1. Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients.
Liu R; Hao S; Zhang H; Ma J; Liu X; Xu J; Liu X; Ning J; Sun Y; Jiang L; Li G; Song X; Zheng H
Oncotarget; 2017 Sep; 8(43):74129-74138. PubMed ID: 29088773
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma.
Zhou C; Li J; Wang Y; Xue S; Zhang Y
Oncol Lett; 2019 Jan; 17(1):183-194. PubMed ID: 30655754
[TBL] [Abstract][Full Text] [Related]
3. The Role of
Klimaitė R; Kazokaitė M; Kondrotienė A; Daukšienė D; Sabaliauskaitė R; Žukauskaitė K; Žilaitienė B; Jarmalaitė S; Daukša A
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013156
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of benign thyroid nodules from malignant thyroid nodules through miR-205-5p and thyroid-stimulating hormone receptor mRNA.
Zhou J; Cao L; Chen Z
Hormones (Athens); 2021 Sep; 20(3):571-580. PubMed ID: 33788150
[TBL] [Abstract][Full Text] [Related]
5. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.
Liu TR; Su X; Qiu WS; Chen WC; Men QQ; Zou L; Li ZQ; Fu XY; Yang AK
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3582-91. PubMed ID: 27649658
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of thyroid-stimulating hormone receptor mRNA with real-time PCR for early diagnosis of papillary thyroid microcarcinoma.
Qiu J; Zhang Y; Guo X; Zeng F; Zhao C; Qiu X; Wu X
Neoplasma; 2010; 57(4):360-4. PubMed ID: 20429628
[TBL] [Abstract][Full Text] [Related]
7. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
[TBL] [Abstract][Full Text] [Related]
8. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.
Qu M; Wan S; Ren B; Wu H; Liu L; Shen H
Endocrine; 2020 Sep; 69(3):508-515. PubMed ID: 32279226
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
Oler G; Cerutti JM
Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
11. Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor.
Zheng H; Xu J; Hao S; Liu X; Ning J; Song X; Jiang L; Liu Z
Oncol Lett; 2018 Aug; 16(2):2009-2015. PubMed ID: 30034553
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
[TBL] [Abstract][Full Text] [Related]
16. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
17. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
18. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples.
Milas M; Shin J; Gupta M; Novosel T; Nasr C; Brainard J; Mitchell J; Berber E; Siperstein A
Ann Surg; 2010 Oct; 252(4):643-51. PubMed ID: 20881771
[TBL] [Abstract][Full Text] [Related]
19. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
20. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
